



NDA 50-796/S-004

B. Braun Medical, Inc.  
Attention: Susan Olinger  
Corporate Vice President, Regulatory Affairs  
901 Marcon Boulevard  
Allentown, PA 18109

Dear Ms. Olinger:

Please refer to your supplemental new drug application dated March 7, 2007, received March 12, 2007 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ceftriaxone for Injection and Dextrose Injection in the Duplex<sup>®</sup> Container, 1g Ceftriaxone and 2g Ceftriaxone.

This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This "Changes Being Effected" supplemental new drug application provides for revisions to the package insert to include information relative to recent epidemiologic and scientific data regarding *Clostridium difficile* associated disease (CDAD).

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on March 7, 2007.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
5515 Security Lane  
HFD-001, Suite 5100  
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Regulatory Project Manager, at (301) 796-0702.

Sincerely,

*{See appended electronic signature page}*

Katherine A. Laessig, MD  
Deputy Director  
Division of Anti-Infective and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosure: Labeling submitted on March 7, 2007

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Kathrine Laessig  
9/10/2007 09:58:17 AM